- Home
- NXL vs ICU Comparison
NXL vs ICU Comparison
Compare NXL & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- ICU
- Stock Information
- Founded
- NXL 2010
- ICU 2018
- Country
- NXL United States
- ICU United States
- Employees
- NXL N/A
- ICU N/A
- Industry
- NXL Medical Specialities
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- NXL Health Care
- ICU Health Care
- Exchange
- NXL Nasdaq
- ICU Nasdaq
- Market Cap
- NXL 17.8M
- ICU 15.9M
- IPO Year
- NXL 2022
- ICU N/A
- Fundamental
- Price
- NXL $1.52
- ICU $0.61
- Analyst Decision
- NXL Strong Buy
- ICU
- Analyst Count
- NXL 1
- ICU 0
- Target Price
- NXL $5.00
- ICU N/A
- AVG Volume (30 Days)
- NXL 10.4M
- ICU 4.1M
- Earning Date
- NXL 11-07-2025
- ICU 11-12-2025
- Dividend Yield
- NXL N/A
- ICU N/A
- EPS Growth
- NXL N/A
- ICU N/A
- EPS
- NXL N/A
- ICU N/A
- Revenue
- NXL $174,813.00
- ICU $766,000.00
- Revenue This Year
- NXL $38.28
- ICU $820.00
- Revenue Next Year
- NXL $185.71
- ICU $63.37
- P/E Ratio
- NXL N/A
- ICU N/A
- Revenue Growth
- NXL 16.42
- ICU N/A
- 52 Week Low
- NXL $0.70
- ICU $0.31
- 52 Week High
- NXL $4.49
- ICU $4.28
- Technical
- Relative Strength Index (RSI)
- NXL 61.70
- ICU 43.42
- Support Level
- NXL $1.20
- ICU $0.51
- Resistance Level
- NXL $1.46
- ICU $0.74
- Average True Range (ATR)
- NXL 0.17
- ICU 0.07
- MACD
- NXL 0.04
- ICU -0.00
- Stochastic Oscillator
- NXL 57.89
- ICU 45.91
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.